News

Exagen Showcases Innovative Abstracts at National Rheumatology Event

Exagen Showcases Innovative Abstracts at National Rheumatology Event

Exagen's Participation at ACR Convergence 2024

Exagen Inc. (NASDAQ: XGN), a renowned leader in autoimmune diagnostic solutions, has exciting news! The company announced that five of its abstracts have been accepted for presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024. This prestigious annual meeting is set to take place mid-November, showcasing cutting-edge research and advancements in rheumatology.

Highlighting Innovative Research

One of the key highlights of Exagen’s contributions will be a plenary presentation developed alongside esteemed researchers from Johns Hopkins University. This presentation will feature a groundbreaking urinary biomarker panel designed to aid in the precise management of Lupus Nephritis. Such advancements are crucial for rheumatologists aiming to enhance patient outcomes.

In addition to the main presentation, Exagen will also showcase innovative findings from research focusing on novel T Cell biomarkers associated with Lupus and specific anti-RA33 autoantibodies related to rheumatoid arthritis. These findings are anticipated to greatly enhance diagnostic sensitivity for conditions assessed by the AVISE CTD platform, thereby transforming the landscape of autoimmune diagnostics.

Statements from Leadership

Expressing the company’s dedication to innovation, Dr. Andrew Concoff, Chief Innovation Officer at Exagen, remarked, “Our research highlights our commitment to pioneering new biomarkers that advance rheumatologic care. We eagerly await the opportunity to share these findings with the broader rheumatology community to enhance patient care.”

Accepted Abstracts Overview

Exagen's accepted abstracts reflect its dedication to leading advancements in autoimmune diagnostics:

Collaborative Plenary Presentation

Title: A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis
Presented by: Andrea Fava
Session Date and Time: Sunday, November 17, from 9:00 a.m. – 9:15 a.m. ET

Poster Presentations on Novel Biomarkers

Title: Multi-centered Clinical Validation of T Cell-bound C4d and T Cell Autoantibodies
Presented by: Vasileios Kyttaris
Session Date and Time: Sunday, November 17, from 10:30 a.m. – 12:30 p.m. ET

Title: Maximizing Diagnostic Sensitivity
Presented by: Andrew Concoff
Session Date and Time: Monday, November 18, from 10:30 a.m. – 12:30 p.m. ET

Title: Unique Biomarkers for Identifying Seronegative Rheumatoid Arthritis
Presented by: Andrew Concoff
Session Date and Time: Monday, November 18, from 10:30 a.m. – 12:30 p.m. ET

Title: Added Value of CB-CAPs in Large Validation Cohort
Presented by: Andrew Concoff
Session Date and Time: Saturday, November 16, from 10:30 a.m. – 12:30 p.m. ET

About Exagen Inc.

Exagen Inc. is at the forefront of providing diagnostic clarity to patients grappling with autoimmune diseases. With its headquarters nestled in California, the company's mission revolves around delivering accurate and timely diagnosis to improve clinical outcomes. The flagship AVISE CTD product enables healthcare providers to identify complex autoimmune conditions, such as lupus and rheumatoid arthritis, with enhanced precision. Exagen’s laboratory is known for its specialization in rheumatic diseases, offering a comprehensive suite of AVISE-branded tests that facilitate diagnosis, prognosis, and monitoring.

Through persistent research and an unwavering focus on patient-centric care, Exagen is committed to advancing the understanding and management of autoimmune diseases.

Frequently Asked Questions

What abstracts did Exagen present at ACR Convergence 2024?

Exagen presented five abstracts, including a collaboration with Johns Hopkins University focusing on a urinary biomarker panel for Lupus Nephritis.

Who is the Chief Innovation Officer at Exagen?

Dr. Andrew Concoff serves as the Chief Innovation Officer at Exagen and expresses the company's commitment to innovative research.

What is the AVISE CTD product?

AVISE CTD is Exagen's flagship diagnostic tool designed to help clinicians diagnose complex autoimmune conditions with greater accuracy.

When is the ACR Convergence 2024 meeting scheduled?

The ACR Convergence 2024 meeting will take place from November 14 to November 19.

How does Exagen contribute to rheumatology care?

Exagen provides advanced diagnostic tests that enhance the sensitivity and specificity of autoimmune disease diagnosis, aiming to improve patient care outcomes.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 332

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 199

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 509

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 47

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 19

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 287

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 78

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 241

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading

Top 5 Most Recently Viewed Articles

Liberty Tire Recycling Raises Substantial Funds for Childhood Hunger

Updated Category News Views 47

Liberty Tire Recycling's Philanthropic Efforts Liberty Tire Recycling has impressively raised $87,805 to support Blessings in a Backpack, an organization dedicated to combating childhood hunger. This significant amount was a result of several engaging events, including a charity golf tournament and multiple packing sessions, where employees actively participated....

Continue Reading
Future of Surface Disinfectant Products and Market Growth

Updated Category News Views 184

Growth of the Surface Disinfectant Products Market The surface disinfectant products market is on a promising trajectory, forecasted to reach USD 65.7 billion by 2035, with a compound annual growth rate (CAGR) of 4.8% starting in 2025. This growth reflects a broader trend towards increased consciousness around hygiene and health safety, particularly in light of recent...

Continue Reading
Cryptocurrency Market Update: Bitcoin and Ethereum Trends

Updated Category News Views 226

Cryptocurrency Market Overview As of Tuesday morning, the cryptocurrency market is experiencing a decline, with Bitcoin's price falling to $113,000 amidst ongoing negotiations regarding a government shutdown in the U.S. This pivotal moment has left investors analyzing market movements closely. Key Cryptocurrency Prices The current prices for major cryptocurrencies are as...

Continue Reading
Market Positioning Insights and Risks: What Investors Should Know

Updated Category News Views 68

S&P 500 Positioning Risks Highlighted by Citi Recent analysis by Citi strategists reveals concerning trends in the S&P 500's positioning, now at levels not seen in the past three years. This significant rise in positioning makes the index noticeable among other markets, where investor conviction remains unsteady. Understanding Market Pullbacks Historical data emphasizes a...

Continue Reading
Galmed Pharmaceuticals Unveils Innovative Digital Asset Strategy

Updated Category News Views 126

Galmed Pharmaceuticals' Strategic Move into Digital Assets Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), a clinical-stage biopharmaceutical company specializing in the treatment of various diseases, has embarked on an innovative journey that dives into digital asset management. This strategic decision aims to enhance capital efficiency and bolster shareholder value through...

Continue Reading